Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Evolving Clinical Considerations for Breast Cancer Brain Metastases: Expert Case Discussions
  • CME
  • MOC

Credits Available
Physicians: maximum of 1.25 AMA PRA Category 1 Credits
ABIM MOC: maximum of 1.25 Medical Knowledge MOC point(s)
Released: January 22, 2021 Expiration: January 21, 2022
Start Activity
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Genentech, a member of the Roche Group
Puma Biotechnology, Inc.
Ruth O'Regan, MD
Lee Schwartzberg, MD, FACP

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Discuss the risk factors associated with CNS metastases in patients with breast cancer
  • Evaluate available and emerging clinical data on the use of systemic therapies to treat breast cancer brain metastases
  • Incorporate expert consensus and guideline recommendations into practice taking a multidisciplinary team approach to treatment
  • Integrate new therapeutic approaches into clinical practice for patients with brain metastases from breast cancer based on individual patient and tumor characteristics

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Ruth O'Regan, MD

Professor
Division of Hematology/Oncology
Department of Medicine
UW School of Medicine and Public Health
UW Carbone Cancer Center
University of Wisconsin–Madison
Madison, Wisconsin

Ruth O’Regan, MD, has disclosed that she has received funds for research support from Novartis, Pfizer, Puma, and Seattle Genetics and consulting fees from Biotheranostics, Cyclacel, MacroGenics, Novartis, Pfizer, Puma, and Seattle Genetics.
Lee Schwartzberg, MD, FACP

Medical Director
West Cancer Center and Research Institute
Germantown, Tennessee
Chief Medical Director
One Oncology
Memphis, Tennessee

Lee Schwartzberg, MD, FACP, has disclosed that he has received funds for research support from Amgen and consulting fees from Amgen, AstraZeneca, Bristol-Myers Squibb, Genentech/Roche, Genomic Health, Helsinn, Myriad, Napo, Pfizer, and Spectrum and other financial support from Bayer.

Staff

Rachael M. Andrie, PhD

Scientific Director

Rachael Andrie, PhD, has no relevant conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for oncologists and other clinicians involved in the management of metastatic breast cancer patients with CNS metastases.

Goal

The goal of this activity is to improve the competence and performance of learners to apply practice-changing clinical data and expert recommendations regarding the treatment of patients with metastatic breast cancer and CNS metastases.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification

Successful completion of this activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 22, 2021, through January 21, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Current Evidence on Therapeutic Approaches to BCBM: HER2-Positive Disease
  • CME
  • MOC

Ruth O'Regan, MD
Lee Schwartzberg, MD, FACP
Physicians: maximum of 1.25 AMA PRA Category 1 Credits
ABIM MOC: maximum of 1.25 Medical Knowledge MOC point(s)
Released: January 22, 2021 Expiration: January 21, 2022

This program is divided into several short segments that you can step through using the Video Chapters menu.

Related Content

Clinical Care Options (CCO) expert podcast of top leukemia presentations from Hematology 2020: magrolimab in AML, asciminib in CML (ASCEMBL), ponatinib dosing in CML (OPTIC)

Jorge Cortes, MD Eunice S. Wang, MD Released: February 26, 2021

From Clinical Care Options (CCO), Drs. Jeff Sharman and John Burke review key data from studies of lymphomas and CLL treatment presented at ASH 2020

John M. Burke, MD Jeff P. Sharman, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: February 26, 2021 Expired: February 25, 2022

Slides on checkpoint inhibitors in first-line, second-line, and maintenance settings for urothelial carcinoma, from Clinical Care Options (CCO)

Cora N. Sternberg, MD, FACP Released: February 26, 2021

Slides on erdafitinib, enfortumab vedotin, and sacituzumab govitecan for progressive urothelial carcinoma, from Clinical Care Options (CCO)

Petros Grivas, MD, PhD Released: February 26, 2021

Video Chapters


Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Genentech, a member of the Roche Group
Puma Biotechnology, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue